UK: IPF – Second Wave Of Asbestosis Claims?

Last Updated: 5 October 2017
Article by Toby Scott


Idiopathic Pulmonary Fibrosis (IPF) is a condition in which the lungs become scarred and breathing becomes increasingly difficult.

IPF is commonly identified by a diagnosis of exclusion; essentially a diagnosis of lung fibrosis of unknown cause.

The incidence of IPF is much higher than the incidence of asbestosis, and has risen steadily in the UK in recent decades. Current annual death rates of 6,000 are seen. IPF can affect people of all ages, but around 85% of diagnoses are made in patients over 70 years of age.

Claimants who have been unable to establish an asbestosis diagnosis (for example because they cannot establish an exposure history which exceeds the conventional threshold of 25 fibre ml years) are often re-categorised as suffering from IPF which, as a condition of unknown cause, is self evidentially non-compensatable.

However assumptions in this area have been called into question in a paper prepared by members of the Health and Safety Laboratory in Buxton (UK Asbestos Imports and Mortality due to Idiopathic Pulmonary Fibrosis)

The authors sought to compare mortality data as a result of mesothelioma, asbestosis and IPF, with asbestos imports.  

The paper made the following conclusions:

  1. A rising IPF mortality rate has been seen, without any apparent explanation;
  2. A linear relationship between mortality for mesothelioma and IPF (and a less strong relationship for asbestosis mortality) and historic UK asbestos import statistics.
  3. A strength of association between IPF and historical imports similar to that in mesothelioma.
  4. Accepting that previous studies failed to establish any risk factors from IPF, the strength of relationship between IPF mortality and historical asbestos imports raises a question of whether a proportion of IPF mortality is due to unrecognised asbestos exposures.


Asbestos claimants are often elderly and provide poor exposure histories. Possible explanations for this include the time elapsed since the exposure occurred, indirect exposure as a bystander, and handling materials that at the time were not identified as containing asbestos.

Where an exposure assessment concludes that the generally accepted asbestosis threshold of 25 fibre ml years (lifetime exposure) is not met, a diagnosis of IPF is preferred to one of asbestosis.

The authors inevitably question whether a 25 fibre ml year threshold is realistic in view of their own findings and also those of previous studies. They cite as an example the Dutch practice of accepting an asbestosis diagnosis with a history above a 5 fibre ml threshold.

They raise the questions of whether there is a need for a more accurate method of assessing lifetime occupational asbestos exposure and whether existing diagnosed cases of IPF should be re-categorised as asbestosis cases.

In a later article ( the authors advocate the formulation of an occupation based risk matrix as a potential solution to overcoming difficulties of establishing causation.

The British Lung Foundation estimates in excess of 30,000 people in the UK currently suffer from IPF and it is estimated that 6,000 new cases will be diagnosed annually. In British Lung Foundation data, the incidence rate increases dramatically with age and it is therefore unsurprising that the death rate (based on entries in death certificates) is also so high.

In contrast, the incidence rate for asbestosis (assessed for IIDB purposes) was 1,175 in 2015, reflecting a long term upward trend. The established causes of IPF are varied with fibrosis being created in response to damage of the lung arising from smoking, acid reflux, viruses, family history and also environmental factors (including dust/spore inhalation, including asbestos).

IPF therefore shares several of the demographic risk factors of asbestosis mortality, yet epidemiological studies of IPF have not identified links with previous asbestos exposure. Certain occupations have however been linked with an increased risk of IPF in Britain, particularly workers exposed to metal and wood dusts.

What this means for insurers

The authors of this paper acknowledge that the linear relationship between asbestos imports and the incidence of IPF, whilst statistically significant, fall short of confirmatory of medical causation in individual cases. Nevertheless the fact that the relationship is similar to that seen from mesothelioma mortality will undoubtedly serve to encourage further research in this area. Cases need close scrutiny because it is sometimes possible to challenge causation on the basis of radiology and clinical signs and symptoms (see footnote).

Accordingly it will also be likely to encourage claimants and their medical experts in challenging the applicability of the threshold on the basis of the emerging evidence based to the effect that an absolute threshold requirement does not take account of individual susceptibility to fibrosis.

Claimants, without alternative explanations, will undoubtedly be encouraged down this route and there is therefore the prospect of significant increases in asbestosis claim numbers if current and future epidemiology supports an asbestosis diagnosis. A risk based matrix would undoubtedly assist claimants seeking to establish an asbestos cause for IPF, particularly where individual case evidence is deficient.

Equally, claimant experts may wish to challenge existing IPF diagnosis even in cases of lower lifetime exposures where other known causes of IPF do not apply. Insurers have seen reducing asbestosis claim numbers in recent years, but this study provides an example of why optimism in this area may be misplaced.


  • A study using HRCT scans found there was a significant difference between IPF and asbestosis in pleural changes. In addition, there were significant differences between IPF and asbestosis in several parenchymal abnormalities on CT, especially in the less advanced stage of both diseases. On multivariate analysis, HRCT features that distinguished asbestosis from IPF were sub-pleural lines at a distance of less than 5 mm from the inner chest wall, sub-pleural dots and parenchymal bands. In conclusion it was found there are significant differences between IPF and asbestosis in the parenchymal and pleural abnormalities on CT. (
  • UIP pattern fibrosis is rarely observed in asbestos-exposed subjects, and shows no dose–response correlation with asbestos fibres on mineral analysis; this points to an alternative disease, such as IPF. The results indicate that UIP pattern fibrosis should not be regarded as genuine asbestosis, irrespective of the status of asbestos biomarkers, and this impacts upon the post-mortem handling of asbestos-related deaths. (

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions